In this episode, Andrew F. Alexis, MD, MPH; Daniel C. Butler, MD; and Shawn G. Kwatra, MD, discuss IL-13 inhibition for treating patients with moderate to severe atopic dermatitis (AD), including:

• The available biologic therapies that specifically target IL-13
• Where these agents fall in the 2024 American Academy of Dermatology treatment algorithm
• How these agents compare to other AD therapies like topical corticosteroids and oral JAK inhibitors
• A detailed patient case to highlight take home points

Presenter

Andrew F. Alexis, MD, MPH​
Professor of Clinical Dermatology​
Weill Cornell Medical College ​
New York, New York

Daniel C. Butler, MD​
Assistant Dean Student Affairs​
University of Arizona College of Medicine – Tucson​
Tucson, Arizona

Shawn G. Kwatra, MD​
Dr. Joseph W. Burnett Endowed Professor and Chair ​
Department of Dermatology​
University of Maryland School of Medicine​
Baltimore, Maryland

Program page:
https://bit.ly/4kTP04D

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.